Drug intelligence / Profile preview

CNT-CNS-4

Development stage: Preclinical
Lead developer: Centurion
Modality: Small Molecules
Administration: Parenteral

Overview

CNT-CNS-4 is a small molecule therapeutic candidate currently in development by Centurion (Centurion İlaç) for the treatment of nervous system disorders. The drug is formulated as a vial for parenteral administration. While specific details regarding its biological target and mechanism of action are not publicly disclosed, it is part of Centurion's extensive R&D pipeline focused on central nervous system (CNS) indications. The program is currently in the early stages of development, with its specific phase and primary indication within the nervous system category yet to be formally announced.

Beyond the preview

Go deeper on CNT-CNS-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNT-CNS-4.

Explore the full profile